Trial Profile
An Open Label Expanded Access Program Intended to Provide Treatment With HBS-101 (Pitolisant) to Adult Patients in the U.S. With Excessive Daytime Sleepiness Associated With Narcolepsy With or Without Cataplexy
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 27 Aug 2020
Price :
$35
*
At a glance
- Drugs Pitolisant (Primary)
- Indications Narcolepsy
- Focus Expanded access; Therapeutic Use
- Acronyms PEACE
- Sponsors Harmony Biosciences
- 24 Aug 2020 According to a Harmony Biosciences media release, final analysis data from this study will be presented at the upcoming 34th Annual Meeting of the Associated Professional Sleep Societies (APSS), known as "SLEEP 2020." The meeting is being held virtually from August 27th-30th. Abstracts of the WAKIX data will also be published in the journal SLEEP as an online supplement.
- 02 Jun 2020 According to a Harmony Biosciences media release, data from this study were presented at the American Academy of Neurology (AAN) Science, a highlights virtual platform and were published in the journal Neurology in the "Sleep Medicine: Focus on Therapies 2" poster session.
- 01 May 2020 Results assessing safety and tolerability were presented at the 72nd Annual Meeting of the American Academy of Neurology